Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants

Show simple item record

dc.contributor.author Shi, Xiaoguang
dc.contributor.author Liu, Rengyun
dc.contributor.author Basolo, Fulvio
dc.contributor.author Giannini, Riccardo
dc.contributor.author Shen, Xiaopei
dc.contributor.author Teng, Di
dc.contributor.author Guan, Haixia
dc.contributor.author Shan, Zhongyan
dc.contributor.author Teng, Weiping
dc.contributor.author Musholt, Thomas J.
dc.contributor.author Al-Kuraya, Khawla
dc.contributor.author Fugazzola, Laura
dc.contributor.author Colombo, Carla
dc.contributor.author Kebebew, Electron
dc.contributor.author Jarzab, Barbara
dc.contributor.author Czarniecka, Agnieszka
dc.contributor.author Bendlova, Bela
dc.contributor.author Sykorova, Vlasta
dc.contributor.author Sobrinho-Simoes, Manuel
dc.contributor.author Soares, Paula
dc.contributor.author Shong, Young Kee
dc.contributor.author Kim, Tae Yong
dc.contributor.author Cheng, Sonia
dc.contributor.author Asa, Sylvia L.
dc.contributor.author Viola, David
dc.contributor.author Elisei, Rossella
dc.contributor.author Yip, Linwah
dc.contributor.author Mian, Caterina
dc.contributor.author Vianello, Federica
dc.contributor.author Wang, Yangang
dc.contributor.author Zhao, Shihua
dc.contributor.author Oler, Gisele [UNIFESP]
dc.contributor.author Cerutti, Janete Maria [UNIFESP]
dc.contributor.author Puxeddu, Efisio
dc.contributor.author Qu, Shen
dc.contributor.author Wei, Qing
dc.contributor.author Xu, Huixiong
dc.contributor.author O'Neill, Christine J.
dc.contributor.author Sywak, Mark S.
dc.contributor.author Clifton-Bligh, Roderick
dc.contributor.author Lam, Alfred K.
dc.contributor.author Riesco-Eizaguirre, Garcilaso
dc.contributor.author Santisteban, Pilar
dc.contributor.author Yu, Hongyu
dc.contributor.author Tallini, Giovanni
dc.contributor.author Holt, Elizabeth H.
dc.contributor.author Vasko, Vasily
dc.contributor.author Xing, Mingzhao
dc.date.accessioned 2019-01-21T10:29:57Z
dc.date.available 2019-01-21T10:29:57Z
dc.date.issued 2016
dc.identifier https://doi.org/10.1210/jc.2015-2917
dc.identifier.citation Journal Of Clinical Endocrinology & Metabolism. Cary, v. 101, n. 1, p. 263-273, 2016.
dc.identifier.issn 0021-972X
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/49497
dc.description.abstract Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support. Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC). Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo). Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC >> FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval [CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old. Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC >> FVPTC, providing important clinical implications for specific variant-based management of PTC. en
dc.description.sponsorship US National Institutes of Health (NIH) [RO1CA113507, R01CA189224]
dc.description.sponsorship National Science Centre Poland (Poland) [N403 194340, N N401 612440, 267398]
dc.description.sponsorship Queensland Government (Australia)
dc.description.sponsorship Griffith Health Institute (Australia)
dc.description.sponsorship Fondazione Cassa di Risparmio di Perugia (Italy)
dc.description.sponsorship Associazione Italiana per la Ricerca sul Cancro (Italy) [IG 9338]
dc.description.sponsorship Beadle Family Foundation (San Antonio, TX)
dc.description.sponsorship New South Wales Cancer Institute (Australia)
dc.description.sponsorship Cancer Council of New South Wales (Australia)
dc.description.sponsorship Italian Government-Ministero della Salute (Italy) [RF-2011-02350857]
dc.description.sponsorship Ministerodella Istruzione Universitaria e Ricerca Scientifica (Italy)
dc.description.sponsorship AssociazioneItaliana per la Ricerca sul Cancro (Italy)
dc.description.sponsorship Istituto Toscano Tumori (Italy)
dc.description.sponsorship Ministero della Salute (Italy)
dc.description.sponsorship Korean Foundation for Cancer Research (South Korea) [CB-2011-03-02]
dc.description.sponsorship Sao Paulo State Research Foundation (FAPESP) [2012/02902-9, 2013/03867-5]
dc.description.sponsorship AIRC (Italy) [IG 10316]
dc.description.sponsorship Shanghai Hospital Development Center (China) [SHDC 12014229]
dc.description.sponsorship Programa Operacional Regional do Norte (ON.2-O Novo Norte), under the Quadro de Referencia Estrategico Nacional
dc.description.sponsorship Fundo Europeu de Desenvolvimento Regional
dc.description.sponsorship [RD12/0036/0030 FIS-ISCIII]
dc.description.sponsorship [S2011/BMD-2328 TIRONET]
dc.description.sponsorship [SAF2013-44709-R]
dc.description.sponsorship [IGA MH CR NT 13901-4]
dc.description.sponsorship [NIH/NIA 5R03AG042334-02]
dc.format.extent 263-273
dc.language.iso eng
dc.publisher Oxford univ press inc
dc.relation.ispartof Journal Of Clinical Endocrinology & Metabolism
dc.rights Acesso restrito
dc.subject Braf V600e Mutation en
dc.subject Tall-Cell Variant en
dc.subject Needle-Aspiration Biopsy en
dc.subject Term-Follow-Up en
dc.subject Follicular Variant en
dc.subject Braf(V600e) Mutation en
dc.subject Surgical-Treatment en
dc.subject Clinical-Features en
dc.subject Carcinoma en
dc.subject Association en
dc.title Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants en
dc.type Artigo
dc.description.affiliation Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287
dc.description.affiliation Department of Surgery, Division of Pathology, 56126 Pisa, Italy
dc.description.affiliation The Endocrine Institute and The Liaoning Provincial Key Laboratory of Endocrine Diseases, Department of Endocrinology and Metabolism, The First Hospital of China Medical University, Shenyang, Liaoning Province 110001, China
dc.description.affiliation Endocrine Surgery, University Medical Center, Johannes Gutenberg University Mainz, 55101 Mainz, Germany
dc.description.affiliation Human Cancer Genomic Research, Research Centre, King Faisal Specialist Hospital and Research Centre, Riyadh 12713, Kingdom of Saudi Arabia
dc.description.affiliation Fondazione Instituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Policlinico, Milan, and Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan Italy
dc.description.affiliation Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
dc.description.affiliation Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 44-101 Gliwice, Poland
dc.description.affiliation Department of Molecular Endocrinology, Institute of Endocrinology, Prague 11694, Czech Republic
dc.description.affiliation Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup) and Medical Faculty of the University of Porto, 4200-319 Porto, Portugal
dc.description.affiliation College of Medicine, University of Ulsan College of Medicine, Seoul, South Korea
dc.description.affiliation Department of Pathology, University Health Network, Toronto, ON M5G 2C4 Canada
dc.description.affiliation Endocrine Unit, Department of Clinical and Experimental Medicine, World Health Organization, Collaborating Center for the Study and Treatment of Thyroid Diseases and Other Endocrine and Metabolic Disorders, University of Pisa, 56124 Pisa, Italy
dc.description.affiliation University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213
dc.description.affiliation Department of Medicine, Endocrinology Unit, University of Padua, Padua 35128, Italy
dc.description.affiliation Veneto Institute of Oncology, IRCCS, Padua 35128, Italy
dc.description.affiliation Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China
dc.description.affiliation Genetic Bases of Thyroid Tumor Laboratory, Division of Genetics, Federal University of São Paulo, São Paulo 04039-032, Brazil
dc.description.affiliation Department of Internal Medicine, University of Perugia, 06100 Perugia, Italy
dc.description.affiliation Department of Endocrinology, Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Thyroid Institute, Tongji University School of Medicine, Shanghai, 200072, China
dc.description.affiliation Endocrine Surgical Unit , The University of Sydney, Sydney 2052, Australia
dc.description.affiliation Cancer Molecular Pathology of Menzies Health Institute Queensland, Griffith University–Gold Coast, Southport 4215, Australia
dc.description.affiliation Hospital La Paz, Health Research Institute, and Hospital Universitario de Móstoles, and Biomedical Research Institute, “Alberto Sols,” Spanish Council of Research Consejo Superior de Investigaciones Científicas, and Autonomous University of Madrid, Madrid, 28029 Madrid, Spain
dc.description.affiliation Department of Pathology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
dc.description.affiliation Department of Medicine, Anatomic Pathology Unit, Ospedale Bellaria, University of Bologna, 40139 Bologna, Italy
dc.description.affiliation Endocrine Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520
dc.description.affiliation Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814
dc.description.affiliationUnifesp Genetic Bases of Thyroid Tumor Laboratory, Division of Genetics, Federal University of São Paulo, São Paulo 04039-032, Brazil
dc.description.sponsorshipID NIH: RO1CA113507
dc.description.sponsorshipID NIH: R01CA189224
dc.description.sponsorshipID National Science Centre Poland: N403 194340
dc.description.sponsorshipID National Science Centre Poland: N N401 612440
dc.description.sponsorshipID Milestone: 267398
dc.description.sponsorshipID Queensland Government Smart State Fellowship and Griffith Health Institute: RD12/0036/0030 FIS-ISCIII
dc.description.sponsorshipID Queensland Government Smart State Fellowship and Griffith Health Institute: S2011/BMD-2328 TIRONET
dc.description.sponsorshipID Queensland Government Smart State Fellowship and Griffith Health Institute: SAF2013-44709-R
dc.description.sponsorshipID Fondazione Cassa di Risparmio di Perugia and Associazione Italiana per la Ricerca sul Cancro: IG 9338
dc.description.sponsorshipID IGA MH CR NT: 13901-4
dc.description.sponsorshipID Italian Government-Ministero della Salute:RF-2011-02350857
dc.description.sponsorshipID NIH/NIA: 5R03AG042334-02
dc.description.sponsorshipID Korean Foundation for Cancer Research: CB-2011-03-02
dc.description.sponsorshipID FAPESP: 2012/02902-9
dc.description.sponsorshipID FAPESP: 2013/03867-5
dc.description.sponsorshipID AIRC: IG 10316
dc.description.sponsorshipID Shanghai Hospital Development Center: SHDC 12014229
dc.identifier.doi 10.1210/jc.2015-2917
dc.description.source Web of Science
dc.identifier.wos WOS:000377212700034


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record




My Account